Beyond The Starting Material: Building A Path To GMP Manufacturing Success

A strong cell therapy manufacturing strategy begins with the starting material. Decisions involving donor sourcing, collection methods, material specifications, process development, and analytical controls can shape consistency and manufacturing readiness throughout a program’s lifecycle.

Technical experts from New York Blood Center Enterprises’ Comprehensive Cell Solutions team share practical insights from cellular sourcing and collections through process development, technology transfer, and clinical manufacturing. Key considerations include aligning starting material requirements with downstream processes, establishing fit-for-purpose controls and specifications, and preparing for an effective transition into GMP manufacturing. The discussion also addresses common challenges that emerge as programs advance from early development toward clinical and commercial stages.

Learn how early development decisions can reduce variability, anticipate manufacturing challenges, and support a more reliable path to GMP manufacturing.